GC Cell to present long-term efficacy of Immuncell-LC at ASCO GI 2025

GC Cell said it will present new findings on its autologous cancer immunotherapy, Immuncell-LC, at the ASCO GI 2025 (Gastrointestinal Cancers Symposium) in San Francisco, the U.S., on Jan. 24.

The presentation will be delivered by Professor Lee Jeong-hoon of the Department of Gastroenterology at Seoul National University Hospital, as part of the session titled, “A Novel Immunotherapy Approach for Cholangiocarcinoma, Hepatocellular, and Pancreatic Cancers.”

Professor Lee will discuss the topic, “Adjuvant Cytokine-Induced Killer Cell Immunotherapy in Hepatocellular Carcinoma: Extended Follow-Up of a Randomized Controlled Trial and Post-Treatment Immune Cell Profiling,” which highlights the long-term efficacy results of a nine-year follow-up study from a phase 3 clinical trial conducted in 2015.

Immuncell-LC is the only therapy in its class demonstrating sustained improvements in recurrence-free survival (RFS) and overall survival (OS) for hepatocellular carcinoma (HCC). GC Cell expects that the updated findings will help a field that lacks effective treatment options.

GC Cell anticipates the presentation will attract attention as the company continues to advance immunotherapy for gastrointestinal cancers and establish Immuncell-LC as a key therapeutic option for patients worldwide.